Quarterly Activities/Appendix 4C Cash Flow Report

Oct 30, 2026 at 1:34 AM EDT · Issued by Radiopharm Theranostics Limited via ASX

Filed with ASX · Oct 30, 2026 at 1:34 AM EDT

On 6ix: 6ix.com/news/quarterly-activitiesappendix-4c-cash-flow-report-680

RAD RADIOPHARM THERANOSTICS Quarterly Activities & Cash Report and 4C for the quarter ended 30 September 2026 ASX ANNOUNCEMENT 30 October 2026 Radiopharm Theranostics Reports Business Update Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27...

View Attachment

6ix is reading this filing.

Radiopharm Theranostics Limited on 6ix

Earlier from Radiopharm Theranostics

Radiopharm receives $8M advance on FY26 R&D tax incentiveOct 26
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101Oct 5
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual MeetingSep 14
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal AdenocarcinomaSep 9
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsAug 26

All Radiopharm Theranostics news releases

Follow Radiopharm Theranostics into a list and get an email when it puts out news.

Follow Radiopharm Theranostics